Mosaiques received funding for two projects in the European Personalized medicine initiative:

SIGNAL (Body fluid proteome SIGnatures for persoNALLised intervention to precent cardiovascular and renal complications in diabetes) project targets to evaluate and establish predictive biomarkers that enable guiding anti-diabetic treatment with respect to prevention of chronic kidney and cardiovascular diseases.

UriCoV (URInary peptidomic patterns for Long-COVID syndrome) project aims to investigate in depth the molecular phenotype(s) of individual patients previously infected by SARS-CoV-2 and identify patients at risk of post acute sequale of SARS-CoV-2 infection.

LINK: https://erapermed.isciii.es/wp-content/uploads/2023/02/Newsletter-January-23_final1.pdf